Phase II trial of pembrolizumab, ipilimumab, and aspirin in melanoma: clinical outcomes and translational predictors of response is a research paper published in BJC Reports (2024). On theSindex it has a DataRank of 0.449. It has been cited 19 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.449
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIDDK NIH HHS
Grant: K12 DK133995
NIDDK NIH HHS
Grant: P30 DK063720
NCATS NIH HHS
Grant: UM1 TR004409
National Institutes of Health
Grant: 5P30DK063720-03
ISLET PRODUCTION FACILITY CORE
National Institutes of Health
Grant: 5K12DK133995-03
Diabetes-Docs: Physician-Scientist Career Development Program (DiabDocs)
National Institutes of Health
Grant: 5R00CA246061-04
Developing strategies to inhibit cancer immunotherapy-induced immune-related adverse events without impeding anti-tumor immunity
Merck Sharp & Dohme LLC
Fields of Study
Keywords
Sustainable Development Goals